Recent developments include financial results announcements, new laboratory service contracts, capital infusions, leadership appointments, and strategic partnerships enhancing distribution and patient access.

• Aspira announced third quarter 2025 financial results and provided a business update in November 2025 [N1].
• The company won a laboratory service contract with the University of Texas Medical Branch at Galveston in October 2025 [N2].
• Aspira was welcomed to the OTCQX market by OTC Markets Group in October 2025 [N3].
• Aspira announced an equity capital infusion of $3.06 million through a private placement and warrant exercise in September 2025 [N4].
• The company appointed a new Chief Financial Officer in September 2025 [N5].
• Aspira announced second quarter 2025 financial results and provided a business update in August 2025 [N6].
• Jane Pine Wood was appointed to the Board of Directors in July 2025 [N7].
• Aspira partnered with Dorsata to offer access to over 300 women's health practices and 1.5 million new patients in June 2025 [N8].

Aspira's development of AI-powered, multi-marker diagnostic tests addresses significant unmet needs in gynecologic disease diagnosis, with potential to improve patient outcomes and reduce unnecessary surgeries. The company's FDA-cleared products and ongoing pipeline programs, including ENDOinform and OVAinform, position it to expand its market reach. Strategic partnerships with major laboratories and healthcare providers enhance distribution and patient access. Recent capital infusions and operational restructuring aim to improve financial sustainability. Clinical publications and regulatory endorsements support product credibility and adoption.

Aspira faces substantial financial challenges, including significant net losses, negative cash flows, and limited cash reserves, raising concerns about its ability to continue operations without additional capital. The termination of key non-dilutive funding contracts, such as the ARPA-H ENDOinform contract, may delay product development. The company operates in a competitive diagnostic market with reimbursement uncertainties and regulatory hurdles. Delisting from Nasdaq and trading on OTC markets may impact investor perception and liquidity. Execution risks include successful commercialization, market adoption, and sustaining partnerships amid financial constraints.

Aspira's competitive advantages include its proprietary AI-powered multivariate index assays combining multiple biomarkers and clinical data, FDA regulatory clearances for key products, and a CLIA-certified laboratory enabling in-house testing. The company benefits from established collaborations with leading academic and research institutions, supporting innovation and clinical validation. Its direct sales force and partnerships with major laboratories such as BioReference, ARUP, and Mayo Clinical Laboratories provide broad distribution channels. Aspira's focus on underserved gynecologic diagnostic markets, including ovarian cancer and endometriosis, and its ability to develop novel multi-omic assays contribute to differentiation. However, the company faces challenges from capital constraints and competitive diagnostic technologies.

• Capital and Liquidity Risk: Aspira's current capital resources are insufficient to fund operations through 2026, requiring additional financing or strategic alternatives to sustain operations and advance product development [S1].
• Regulatory and Reimbursement Risk: The company depends on FDA clearances and favorable reimbursement policies, including Medicare coverage, to drive adoption. Delays or denials could impact revenue growth [S1].
• Product Development and Commercialization Risk: Development of new diagnostic tests such as ENDOinform and OVAinform involves scientific, clinical, and regulatory uncertainties. The termination of the ARPA-H contract for ENDOinform may delay commercialization [S1].
• Market Competition and Adoption Risk: Aspira operates in a competitive diagnostic market with alternative technologies. Achieving physician and payer acceptance is critical for commercial success [S1].
• Operational and Execution Risk: The company has undergone significant organizational restructuring and cost reductions. Maintaining skilled personnel and executing commercial strategies effectively are ongoing challenges [S1].

• Aspira Women's Health Inc. develops and commercializes noninvasive, AI-powered diagnostic tests for gynecologic diseases, initially focusing on ovarian cancer [S1].
• The company plans to expand its diagnostic focus to other gynecologic diseases, including endometriosis, targeting an addressable market exceeding 10 million women [S1].
• Aspira owns and operates Aspira Labs, a CLIA-certified clinical laboratory in Texas, performing its tests including Ova1Plus and OvaWatch [S1].
• Key products include the Ova1Plus workflow (combining Ova1 and Overa tests) and OvaWatch, a blood-based risk assessment test for ovarian cancer in women with indeterminate or benign adnexal masses [S1].
• Ova1 received FDA de novo classification in 2009; Overa received FDA 510(k) clearance in 2016; OvaWatch is performed as a laboratory developed test (LDT) [S1].
• The company distributes products through a direct national sales force and channel partnerships with laboratories such as BioReference, ARUP, and Mayo Clinical Laboratories [S1].
• Aspira has collaborations with academic institutions including Johns Hopkins, Dana-Farber Cancer Institute, and others for research and development [S1].
• The company has a product pipeline focused on endometriosis (ENDOinform) and ovarian cancer (OVAinform), developing multi-marker tests combining serum proteins, microRNA, and clinical data [S1].
• Aspira's OvaWatch test has clinical data supporting its use for surgical referral aid and longitudinal monitoring of ovarian cancer risk, with publications in peer-reviewed journals in 2024 [S1].
• Aspira Labs holds multiple accreditations including CLIA, CAP, state licenses in several states, CMS supplier number, and ISO 13485 certification [S1].
• Revenue for the year ended December 31, 2025 was $9.216 million, with a net loss of $12.78 million and basic and diluted EPS of -$0.37 per share [S1].
• As of December 31, 2025, Aspira had cash and cash equivalents of $1.755 million, current assets of $4.063 million, current liabilities of $3.465 million, resulting in a current ratio of 1.17 and a cash ratio of 0.51 [S1].
• The company has experienced significant net losses and negative cash flows from operations since inception, with an accumulated deficit of approximately $544.177 million as of December 31, 2025 [S1].
• Aspira's capital resources are insufficient to fund operations for the remainder of 2026, and the company is pursuing strategic alternatives and additional capital raising [S1].
• In 2025, Aspira executed a strategic shift to reduce cash burn and improve profitability, including headcount reduction and commercial strategy reset [S1].
• Aspira has entered into private placements and equity capital infusions, including a $3.06 million private placement and warrant exercise in 2025 [N4].
• The company was delisted from Nasdaq in April 2025 due to failure to meet listing standards and now trades on the OTCQX market under ticker AWHL [S1][N3].
• Aspira won a laboratory service contract with the University of Texas Medical Branch at Galveston in October 2025 [N2].
• Aspira appointed a new Chief Financial Officer in September 2025 [N5].
• Aspira partnered with Dorsata in June 2025 to offer access to over 300 women's health practices and 1.5 million new patients [N8].
• Aspira announced third quarter 2025 financial results and provided a business update in November 2025 [N1].
• Aspira reached milestones with ARPA-H funding programs but had a contract terminated in June 2025 due to failure to meet milestone specifications, impacting non-dilutive funding for ENDOinform development [S1].